NKGen Biotech Statistics
Total Valuation
NKGen Biotech has a market cap or net worth of 7.84 million. The enterprise value is 46.02 million.
| Market Cap | 7.84M |
| Enterprise Value | 46.02M |
Important Dates
The next estimated earnings date is Friday, April 17, 2026.
| Earnings Date | Apr 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NKGen Biotech has 130.60 million shares outstanding. The number of shares has increased by 98.13% in one year.
| Current Share Class | 130.60M |
| Shares Outstanding | 130.60M |
| Shares Change (YoY) | +98.13% |
| Shares Change (QoQ) | +156.74% |
| Owned by Insiders (%) | 19.31% |
| Owned by Institutions (%) | 2.11% |
| Float | 65.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -0.16 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.95 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05
| Current Ratio | 0.05 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.10 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -93.33% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 85.61% |
| Weighted Average Cost of Capital (WACC) | 5.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -905,923 |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NKGen Biotech has paid 53,000 in taxes.
| Income Tax | 53,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.04% in the last 52 weeks. The beta is 0.95, so NKGen Biotech's price volatility has been similar to the market average.
| Beta (5Y) | 0.95 |
| 52-Week Price Change | -87.04% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.14 |
| Relative Strength Index (RSI) | 62.28 |
| Average Volume (20 Days) | 7,987 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 83.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -24.01M |
| Pretax Income | -23.50M |
| Net Income | -23.55M |
| EBITDA | -22.78M |
| EBIT | -24.01M |
| Earnings Per Share (EPS) | -1.23 |
Balance Sheet
The company has 6,000 in cash and 38.19 million in debt, with a net cash position of -38.19 million or -0.29 per share.
| Cash & Cash Equivalents | 6,000 |
| Total Debt | 38.19M |
| Net Cash | -38.19M |
| Net Cash Per Share | -0.29 |
| Equity (Book Value) | -50.33M |
| Book Value Per Share | -0.98 |
| Working Capital | -41.51M |
Cash Flow
| Operating Cash Flow | -19.65M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NKGen Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -98.13% |
| Shareholder Yield | -98.13% |
| Earnings Yield | -300.58% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |